Internal deletion mutants of soluble T4(CD4)
US5422274A · kind A · utility
Assignees
Inventors
Key dates
| Filing date | Feb 5, 1992 |
| Grant date | Jun 6, 1995 |
| Priority date | — |
| Expiry date | Feb 5, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S930/221
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention provides a therapeutic agent capable of specifically forming a complex with human immunodeficiency virus envelope glycoprotein which comprises a polypeptide. In one embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185 fused to the amino acid sequence from about +353 to about +371. In another embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +106 fused to the amino acid sequence from about +353 to about +371. In yet a further embodiment of the invention, the amino acid sequence of the polypeptide has the amino acid sequence shown in FIG. 6 from about +1 to about +185. This invention also provides a method for treating a subject infected with a human immunodeficiency virus. The method treats the subject with an effective amount of a pharmaceutical composition having an effective amount of a therapeutic agent of the invention and a pharmaceutically acceptable carrier.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.